Thus, it should be noted that even though the possible relationship between GPX1 polymorphism and the risk of cancer may exist, there is no epidemiological evidence that GPx1 upregulation caused specifically by Se supplementation may decrease such a risk, and that such supplementation should be especially beneficial in GPX1 LeuLeu individuals with a low Se status. Here, GPX1 is linked to cancer.